Immix Biopharma Investor Presentation Deck

Proportion of NXC-201 Patients with SCR/CR Increased Over Time in Relapsed/Refractory Multiple Myeloma 100% 80% 60% 40% 20% 0% 50% 31% 2% 17% ■ Best response in patients with at least 1 month follow up SD PR VGPR 75% 25% SCR/CR Best response in patients with at least 6 months follow up 83% 17% ●●● IMMIX S BIOPHARMA Best response in patients with at least 9 months follow up The patients included in this analysis are determined by those who have had their 1- (n=42), 6-(n-16), 9- (n=6) month follow-up visits, respectively, per protocol. Source: Point-of-care CART manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Bloos 37 and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11., Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421., Note: SD = Stable Disease; PR = Partial Response; VGPR = Very Good Partial Response; SCR = stringent (10-5) Complete Response; CR = Complete Response

View entire presentation